A Phase 1b, 12-Week, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Repeated Subcutaneous Administrations of PF-06946860 In Patients with Non-Small Cell Lung Cancer and Cachexia
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
August 13, 2020
End Date
January 25, 2023
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
August 13, 2020
End Date
January 25, 2023